Association of variants in the ABCB1, CYP2C19 and CYP2C9 genes for Juvenile Myoclonic Epilepsy

被引:0
|
作者
Jara-Prado, Aurelio [1 ]
Guerrero-Camacho, Jorge Luis [1 ]
Angeles-Lopez, Quetzalli Denisse [2 ]
Ochoa-Morales, Adriana [1 ]
de Montellano, David Jose Davila-Ortiz [1 ]
Ramirez-Garcia, Miguel Angel [1 ]
Breda-Yepes, Michelle [3 ]
Duron, Reyna M. [4 ]
Delgado-Escueta, Antonio V. [5 ]
Barrios-Gonzalez, Diego A. [3 ]
Martinez-Juarez, Iris E. [3 ]
机构
[1] Natl Inst Neurol & Neurosurg, Genet Dept, Mexico City, Mexico
[2] UNAM, Fac Estudios Super Cuautitlan, Cuautitlan, Mexico
[3] Natl Inst Neurol & Neurosurg, Epilepsy Clin, Mexico City, Mexico
[4] Univ Tecnol Ctr Amer UNITEC, Tegucigalpa, Honduras
[5] UCLA, Dept Neurol, David Geffen Sch Med, Los Angeles, CA USA
关键词
Juvenile Myoclonic Epilepsy; Risk Factor; Genetic Variants; ABCB1; CYPC219; genes; Genes Interaction; BLOOD-BRAIN-BARRIER; BINDING CASSETTE TRANSPORTERS; MDR1; GENE; ULCERATIVE-COLITIS; CYTOCHROMES P450; DRUG-RESISTANCE; P-GLYCOPROTEIN; POLYMORPHISMS; HAPLOTYPES; C3435T;
D O I
10.1007/s10072-023-07124-w
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Juvenile myoclonic epilepsy (JME) is the most common of the generalized genetic epilepsies, with multiple causal and susceptibility genes; however, its etiopathogenesis is mainly unknown. The toxic effects caused by xenobiotics in cells occur during their metabolic transformation, mainly by enzymes belonging to cytochrome P450. The elimination of these compounds by transporters of the ABC type protects the central nervous system, but their accumulation causes neuronal damage, resulting in neurological diseases. The present study has sought the association between single nucleotide genetic variants of the CYP2C9, CYP2C19, and ABCB1 genes and the development of JME in patients compared to healthy controls. The CC1236 and GG2677 genotypes of ABCB1 in women; allele G 2677, genotypes GG 2677 and CC 3435 in men; the CYP2C19*2A allele, and the CYP2C19*3G/A genotype in both sexes were found to be risk factors for JME. Furthermore, carriers of the TTGGCC genotype combination of the ABCB1 gene (1236/2677/3435) have a 10.5 times higher risk of developing JME than non-carriers. Using the STRING database, we found an interaction between the proteins encoded by these genes and other possible proteins. These findings indicate that the CYP450 system and ABC transporters could interact with other genes in the JME.
引用
收藏
页码:1635 / 1643
页数:9
相关论文
共 50 条
  • [1] Association of variants in the ABCB1, CYP2C19 and CYP2C9 genes for Juvenile Myoclonic Epilepsy
    Aurelio Jara-Prado
    Jorge Luis Guerrero-Camacho
    Quetzalli Denisse Ángeles-López
    Adriana Ochoa-Morales
    David José Dávila-Ortiz de Montellano
    Miguel Ángel Ramírez-García
    Michelle Breda-Yepes
    Reyna M. Durón
    Antonio V. Delgado-Escueta
    Diego A. Barrios-González
    Iris E. Martínez-Juárez
    Neurological Sciences, 2024, 45 : 1635 - 1643
  • [2] CYP2C9, CYP2C19, and ABCB1 Genotype and Hospitalization for Phenytoin Toxicity
    Hennessy, Sean
    Leonard, Charles E.
    Freeman, Cristin P.
    Metlay, Joshua P.
    Chu, Xin
    Strom, Brian L.
    Bilker, Warren B.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (12): : 1483 - 1487
  • [3] CYP2C9, CYP2C19 and ABCB1 Genotype and Hospitalization for Phenytoin Toxicity
    Hennessy, Sean
    Leonard, Charles E.
    Palumbo, Cristin M.
    Metlay, Joshua P.
    Chu, Xin
    Strom, Brian L.
    Bilker, Warren B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S22 - S22
  • [4] CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
    A Ortega-Vázquez
    P Dorado
    I Fricke-Galindo
    H Jung-Cook
    N Monroy-Jaramillo
    I E Martínez-Juárez
    I Familiar-López
    E Peñas-Lledó
    A LLerena
    M López-López
    The Pharmacogenomics Journal, 2016, 16 : 286 - 292
  • [5] CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
    Ortega-Vazquez, A.
    Dorado, P.
    Fricke-Galindo, I.
    Jung-Cook, H.
    Monroy-Jaramillo, N.
    Martinez-Juarez, I. E.
    Familiar-Lopez, I.
    Penas-Lledo, E.
    LLerena, A.
    Lopez-Lopez, M.
    PHARMACOGENOMICS JOURNAL, 2016, 16 (03): : 286 - 292
  • [6] Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms
    P Dorado
    E López-Torres
    E M Peñas-LLedó
    J Martínez-Antón
    A LLerena
    The Pharmacogenomics Journal, 2013, 13 : 359 - 361
  • [7] Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms
    Dorado, P.
    Lopez-Torres, E.
    Penas-LLedo, Em
    Martinez-Anton, J.
    LLerena, A.
    PHARMACOGENOMICS JOURNAL, 2013, 13 (04): : 359 - 361
  • [8] CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel
    Peters, Bas J. M.
    Harmsze, Ankie M.
    ten Berg, Jurrien M.
    Maitland-van der Zee, Anke-Hilse
    Tjoeng, Mathieu M.
    de Boer, Anthonius
    Deneer, Vera H. M.
    PHARMACOGENOMICS, 2011, 12 (02) : 141 - 144
  • [9] Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs
    Taur, S. R.
    Kulkarni, N. B.
    Gandhe, P. P.
    Thelma, B. K.
    Ravat, S. H.
    Gogtay, N. J.
    Thatte, U. M.
    JOURNAL OF POSTGRADUATE MEDICINE, 2014, 60 (03) : 265 - 269
  • [10] CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population
    Allabi, AC
    Gala, JL
    Horsmans, Y
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (11): : 779 - 786